270 related articles for article (PubMed ID: 29938471)
1. An Interleukin-6 Single Nucleotide Polymorphism and Susceptibility to Prostate Adenocarcinoma and Bone Metastasis in an Iranian Population.
Dargahi Abbasabad G; Banan Khojasteh SM; Eskandari Naji H; Zamani MR; Hajipour H; Serati-Nouri H
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1717-1720. PubMed ID: 29938471
[TBL] [Abstract][Full Text] [Related]
2. The Role of Interleukin-6 Polymorphism (rs1800795) in Prostate Cancer Development and Progression.
Jurečeková J; Drobková H; Šarlinová M; Babušíková E; Sivoňová MK; Matáková T; Kliment J; Halašová E
Anticancer Res; 2018 Jun; 38(6):3663-3667. PubMed ID: 29848725
[TBL] [Abstract][Full Text] [Related]
3. Interleukins-6 -174G/C (rs1800795) and -572C/G (rs1800796) polymorphisms and prostate cancer risk.
Iqbal MS; Peng K; Sardar N; Iqbal MH; Ghani MU; Tanvir F; Gu D; Guohua Z; Duan X
Mol Immunol; 2023 Dec; 164():88-97. PubMed ID: 37989067
[TBL] [Abstract][Full Text] [Related]
4. IL-6 Genomic Variants and Risk of Prostate Cancer.
Taheri M; Noroozi R; Rakhshan A; Ghanbari M; Omrani MD; Ghafouri-Fard S
Urol J; 2019 Oct; 16(5):463-468. PubMed ID: 30345492
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism.
Wang L; Habuchi T; Mitsumori K; Li Z; Kamoto T; Kinoshita H; Tsuchiya N; Sato K; Ohyama C; Nakamura A; Ogawa O; Kato T
Int J Cancer; 2003 Jan; 103(1):116-20. PubMed ID: 12455063
[TBL] [Abstract][Full Text] [Related]
6. Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer.
Motamedi RK; Sarhangi N; Afshari M; Sattari M; Jamaldini SH; Samzadeh M; Mohsen Ziaei SA; Pourmand GR; Hasanzad M
J Cell Biochem; 2019 Sep; 120(9):14822-14830. PubMed ID: 31017705
[TBL] [Abstract][Full Text] [Related]
7. Interleukin (IL)-8 polymorphisms and risk of prostate disorders.
Taheri M; Noroozi R; Dehghan A; Roozbahani GA; Omrani MD; Ghafouri-Fard S
Gene; 2019 Apr; 692():22-25. PubMed ID: 30641210
[TBL] [Abstract][Full Text] [Related]
8. Role of interleukin-6 gene polymorphisms in the development of prostate cancer.
Chen CH; Gong M; Yi QT; Guo JH
Genet Mol Res; 2015 Oct; 14(4):13370-4. PubMed ID: 26535651
[TBL] [Abstract][Full Text] [Related]
9. Immunogenetics of prostate cancer and benign hyperplasia--the potential use of an HLA-G variant as a tag SNP for prostate cancer risk.
Zambra FM; Biolchi V; de Cerqueira CC; Brum IS; Castelli EC; Chies JA
HLA; 2016 Feb; 87(2):79-88. PubMed ID: 26889902
[TBL] [Abstract][Full Text] [Related]
10. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men.
Takahashi H; Lu W; Watanabe M; Katoh T; Furusato M; Tsukino H; Nakao H; Sudo A; Suzuki H; Akakura K; Ikemoto I; Asano K; Ito T; Wakui S; Muto T; Hano H
Int J Cancer; 2003 Nov; 107(2):224-8. PubMed ID: 12949798
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer.
Wang L; Habuchi T; Tsuchiya N; Mitsumori K; Ohyama C; Sato K; Kinoshita H; Kamoto T; Nakamura A; Ogawa O; Kato T
Cancer Res; 2003 Aug; 63(15):4407-11. PubMed ID: 12907612
[TBL] [Abstract][Full Text] [Related]
12. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
13. Association of IL-1β and IL-10 Polymorphisms with Prostate Cancer Risk and Grade of Disease in Eastern Croatian Population.
Horvat V; Mandić S; Marczi S; Mrčela M; Galić J
Coll Antropol; 2015 Jun; 39(2):393-400. PubMed ID: 26753456
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
[TBL] [Abstract][Full Text] [Related]
15. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
Zambra FM; Biolchi V; Brum IS; Chies JA
Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
[TBL] [Abstract][Full Text] [Related]
16. SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.
Winchester D; Ricks-Santi L; Mason T; Abbas M; Copeland RL; Beyene D; Jingwi EY; Dunston GM; Kanaan YM
Anticancer Res; 2015 Jul; 35(7):3811-9. PubMed ID: 26124326
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 promoter variants, prostate cancer risk, and survival.
Tindall EA; Severi G; Hoang HN; Southey MC; English DR; Hopper JL; Giles GG; Hayes VM;
Prostate; 2012 Dec; 72(16):1701-7. PubMed ID: 22782910
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 polymorphism and prostate cancer risk in population of Eastern Croatia.
Mandić S; Sudarević B; Marczi S; Horvat V; Cosić I; Mihaljević S; Milicević N; Simunović D; Galić J
Coll Antropol; 2013 Sep; 37(3):907-11. PubMed ID: 24308236
[TBL] [Abstract][Full Text] [Related]
19. Relationship between single nucleotide polymorphisms in -174G/C and -634C/G promoter region of interleukin-6 and prostate cancer.
Bao S; Yang W; Zhou S; Ye Z
J Huazhong Univ Sci Technolog Med Sci; 2008 Dec; 28(6):693-6. PubMed ID: 19107369
[TBL] [Abstract][Full Text] [Related]
20. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma.
Jerónimo C; Varzim G; Henrique R; Oliveira J; Bento MJ; Silva C; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):445-50. PubMed ID: 12010858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
